Search research articles
Contact Us
Filters
Showing results (21-30 of 97) with videos related to
Page
of 10
Sort By:
Internal Medicine Journal
|
August 7, 2023
'We are somehow fixated on this being a diabetes drug': a qualitative study exploring the views of cardiologists and nephrologists about sodium-glucose cotransporter 2 inhibitor initiation
Tamara Y Milder, Sophie L Stocker, Melissa T Baysari, et al.
European Journal of Clinical Pharmacology
|
August 5, 2019
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease
Tamara Y Milder, Sophie L Stocker, Dorit Samocha-Bonet, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
June 24, 2018
Clinical Pharmacokinetics in Kidney Disease: Fundamental Principles
Tom N Lea-Henry, Jane E Carland, Sophie L Stocker, et al.
The Journal of Rheumatology
|
February 3, 2011
Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout
Sophie L Stocker, Garry G Graham, Andrew J McLachlan, et al.
The International Journal of Pharmacy Practice
|
April 13, 2022
Clinical interventions to improve adherence to urate-lowering therapy in patients with gout: a systematic review
Klarissa A Sinnappah, Sophie L Stocker, Jian Sheng Chan, et al.
The Journal of Antimicrobial Chemotherapy
|
November 7, 2024
Saliva-based point-of-care assay to measure the concentration of pyrazinamide using a mobile UV spectrophotometer
Ricky Hao Chen, Thi Anh Nguyen, Hannah Yejin Kim, et al.
Clinical Pharmacokinetics
|
July 28, 2007
Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol
Richard O Day, Garry G Graham, Mark Hicks, et al.
Arthritis Research & Therapy
|
December 18, 2010
A proposal for identifying the low renal uric acid clearance phenotype
Praveen L Indraratna, Sophie L Stocker, Kenneth M Williams, et al.
British Journal of Clinical Pharmacology
|
May 21, 2020
Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology
Bradley D Menz, Sophie L Stocker, Nick Verougstraete, et al.
Therapeutic Drug Monitoring
|
November 6, 2024
Untangling the Exposure-Response Relationship of Allopurinol in the Setting of Chronic Kidney Disease and Diuretic Use: Implications for Dosing
Hailemichael Z Hishe, Sophie L Stocker, Lisa K Stamp, et al.
Page
of 10
Search research articles
Search
Showing results (21-30 of 97) with videos related to
Sort By:
Page
of 10
Internal Medicine Journal
|
August 7, 2023
'We are somehow fixated on this being a diabetes drug': a qualitative study exploring the views of cardiologists and nephrologists about sodium-glucose cotransporter 2 inhibitor initiation
Tamara Y Milder, Sophie L Stocker, Melissa T Baysari, et al.
European Journal of Clinical Pharmacology
|
August 5, 2019
Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease
Tamara Y Milder, Sophie L Stocker, Dorit Samocha-Bonet, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
June 24, 2018
Clinical Pharmacokinetics in Kidney Disease: Fundamental Principles
Tom N Lea-Henry, Jane E Carland, Sophie L Stocker, et al.
The Journal of Rheumatology
|
February 3, 2011
Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout
Sophie L Stocker, Garry G Graham, Andrew J McLachlan, et al.
The International Journal of Pharmacy Practice
|
April 13, 2022
Clinical interventions to improve adherence to urate-lowering therapy in patients with gout: a systematic review
Klarissa A Sinnappah, Sophie L Stocker, Jian Sheng Chan, et al.
The Journal of Antimicrobial Chemotherapy
|
November 7, 2024
Saliva-based point-of-care assay to measure the concentration of pyrazinamide using a mobile UV spectrophotometer
Ricky Hao Chen, Thi Anh Nguyen, Hannah Yejin Kim, et al.
Clinical Pharmacokinetics
|
July 28, 2007
Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol
Richard O Day, Garry G Graham, Mark Hicks, et al.
Arthritis Research & Therapy
|
December 18, 2010
A proposal for identifying the low renal uric acid clearance phenotype
Praveen L Indraratna, Sophie L Stocker, Kenneth M Williams, et al.
British Journal of Clinical Pharmacology
|
May 21, 2020
Barriers and opportunities for the clinical implementation of therapeutic drug monitoring in oncology
Bradley D Menz, Sophie L Stocker, Nick Verougstraete, et al.
Therapeutic Drug Monitoring
|
November 6, 2024
Untangling the Exposure-Response Relationship of Allopurinol in the Setting of Chronic Kidney Disease and Diuretic Use: Implications for Dosing
Hailemichael Z Hishe, Sophie L Stocker, Lisa K Stamp, et al.
Page
of 10